Trial Profile
Phase Ib trial of CB 839, combined with pomalidomide and dexamethasone, in patients with myeloma.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Telaglenastat (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Calithera Biosciences
- 05 Oct 2018 According to Calithera Biosciences media release, study eill initiate in 2019
- 13 Jan 2015 New trial record